GFAP and glioblastoma: Moreover, after using on-chip immunofluorescence to measure the concentrations of the GFAP and TAU proteins in EVs, Lewis et al. reported that it is possible to differentiate the plasma of controls from that of glioblastoma patients, with 60% and 94% accuracy, respectively [36].